Actively Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Led by Hoffmann-La Roche · Updated on 2026-04-20
121
Participants Needed
26
Research Sites
359 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
CONDITIONS
Official Title
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- Histologically confirmed B-cell NHL expected to express CD20 antigen
- Relapsed after or failed at least two prior systemic therapies (dose escalation phase)
- Relapsed after or failed at least one prior systemic therapy and need systemic therapy (dose expansion phase for FL Grades 1-3a)
- Relapsed after or failed at least one prior systemic therapy for DLBCL or transformed FL
- For certain patients with only one prior therapy, not candidates for or refused autologous stem cell transplant or ineligible/unable to receive CAR-T therapy
- PET-positive lymphoma confirmed by fluorodeoxyglucose-avid imaging
- At least one measurable nodal lesion >1.5 cm or extranodal lesion >1.0 cm by CT or PET/CT
- Availability of tumor specimen and pathology report confirming diagnosis
- Fresh pretreatment biopsy preferred during screening
- Adequate blood function without recent growth factors or transfusions
- Normal laboratory test results
- Agreement to use effective pregnancy prevention or abstain during and after treatment as specified
You will not qualify if you...
- Pregnancy, breastfeeding, or intention to become pregnant during or shortly after the study
- Prior treatment with cereblon-modulating drugs within 4 weeks before study drugs
- Inability to swallow pills or persistent moderate to severe diarrhea or malabsorption
- QTc interval greater than 470 ms
- Prior treatment with mosunetuzumab, glofitamab, CD20/CD3 bispecific antibodies, allogenic stem cell transplant, or solid organ transplant
- Recent radiotherapy (within 2 weeks), autologous stem cell transplant (within 100 days), CAR-T therapy (within 30 days), or other recent anti-lymphoma therapies as specified
- Live attenuated vaccine within 4 weeks before study or expected during or soon after the study
- Current or past central nervous system lymphoma or leptomeningeal infiltration
- History of severe allergic reactions to monoclonal antibody therapies
- History of autoimmune diseases including myocarditis, pneumonitis, myasthenia gravis, and others
- Major surgery or severe injury within 28 days before enrollment or planned during study
- Unresolved toxicities from prior treatments above Grade 1 except as allowed
- Significant other diseases that could affect study compliance or results
- For glofitamab group, resistance to obinutuzumab monotherapy within 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 26 locations
1
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program
San Francisco, California, United States, 94143
Actively Recruiting
2
University of Colorado
Aurora, Colorado, United States, 80045
Actively Recruiting
3
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
4
The University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
5
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Actively Recruiting
6
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
7
Soroka
Beersheba, Israel, 0084101
Actively Recruiting
8
Rambam Health Care Campus
Haifa, Israel, 3109600
Actively Recruiting
9
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel, 9112001
Actively Recruiting
10
Center Hospital
Ramat Gan, Israel, 5262199
Actively Recruiting
11
Sourasky Medical Center
Tel Aviv, Israel, 6423900
Actively Recruiting
12
IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, Emilia-Romagna, Italy, 40138
Actively Recruiting
13
IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"
Meldola, Emilia-Romagna, Italy, 47014
Actively Recruiting
14
ASST Spedali Civili di Brescia
Brescia, Lombardy, Italy, 25123
Actively Recruiting
15
Irccs Ospedale San Raffaele
Milan, Lombardy, Italy, 20132
Actively Recruiting
16
Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chia
Pisa, Piedmont, Italy, 56126
Actively Recruiting
17
ICO L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Actively Recruiting
18
Hospital Universitario La Fe
Valencia, Valencia, Spain, 46026
Actively Recruiting
19
Hospital Universitari Vall d Hebron
Barcelona, Spain, 08035
Actively Recruiting
20
Clinica Universidad de Navarra-Madrid
Madrid, Spain, 28027
Actively Recruiting
21
Hospital General Universitario Gregorio Maranon
Madrid, Spain, 28040
Actively Recruiting
22
Hosp Universitario Salamanca
Salamanca, Spain, 37007
Actively Recruiting
23
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom, G12 0YN
Actively Recruiting
24
University College London Hospitals
London, United Kingdom, W1T 7HA
Actively Recruiting
25
Nottingham University Hospitals City Campus
Nottingham, United Kingdom, NG5 1PB
Actively Recruiting
26
Oxford University Hospitals NHS Trust - Churchill Hospital
Oxford, United Kingdom, OX3 7LE
Actively Recruiting
Research Team
R
Reference Study ID Number: CO43805 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here